Evaluation of NAD(H) analogues as selective inhibitors for Trypanosoma cruzi S-Adenosylhomocysteine hydrolase by Li, Qing-Shan et al.
Evaluation of NAD(H) analogues as selective inhibitors for
Trypanosoma cruzi S-Adenosylhomocysteine hydrolase
Qing-Shan Li§, Sumin Cai‡, Jianwen Fang#, Ronald T. Borchardt§, Krzysztof Kuczera⊥,‡, C.
Russell Middaugh§, and Richard L. Schowen§,⊥,‡,*
§Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas 66047
⊥Department of Chemistry, The University of Kansas, Lawrence, Kansas 66047
‡Department of Molecular Biosciences, The University of Kansas, Lawrence, Kansas 66047
#Bioinformatics Core Facility, The University of Kansas, Lawrence, Kansas 66047
Abstract
S-Adenosylhomocysteine (AdoHcy) hydrolases (SAHHs) from human sources (Hs-SAHHs) bind
the cofactor NAD+ more tightly than several parasitic SAHHs by around 1000-fold. This property
suggests the cofactor binding site of this essential enzyme as a potential anti-parasitic drug target,
e.g., against SAHH from Trypansoma cruzi (Tc-SAHH). The on-rate and off-rate constants and
the equilibrium dissociation constants were determined for NAD+/NADH analogues and
suggested that NADH analogues were the most promising for selective inhibition of Tc-SAHH.
None significantly inhibited Hs-SAHH while S-NADH and H-NADH (Fig. 1) reduced the
catalytic activity of Tc-SAHH to <10% in six minutes of exposure.
Introduction
During his long and productive career in chemistry, biochemistry, and medicinal chemistry,
Professor Morris J. Robins has created novel nucleosides and other structures, often with
fascinating properties, particularly in their interactions with enzymes. It is our ambition in
this paper to report brief studies in which we attempt to follow in his footsteps.
The parasites Trypanosoma cruzi, Leishmania donovani and Plasmodium falciparum, the
agents of Chagas disease, Leishmaniasis, and malaria, respectively, infect tens of millions in
the less-developed world. Effective, safe, and cheap anti-parasitic medicines are acutely
required. S-adenosyl-L-homocysteine hydrolase ((1) SAHH, EC 3.3.1.1), which catalyzes
the reversible conversion of AdoHcy to adenosine (Ado) and homocysteine (Hcy), has
emerged as a potential molecular target for design of anti-parasitic drugs (2–4). In general,
SAHH inhibition raises the cellular concentration of AdoHcy, a potent product inhibitor of
all S-adenosyl-L-methionine (AdoMet)-dependent methyltransferases. The resulting
inhibition of AdoMet-dependent methylation reactions (1) produces toxic effects. Parasites
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express their own SAHHs (2–4) and anti-parasitic effects of known SAHH inhibitors are
observed in vitro and in vivo for a variety of parasites including L. donovani (5), P.
falciparium (6,7), and Trypanosoma species (8,9) Obviously, only inhibitors specific for the
parasitic enzymes have the potential for medical use.
X-Ray crystallographic structures for Hs-SAHH (10,11), Pf-SAHH (from P. falciparum, 12)
and Tc-SAHH (from T. cruzi, 13) are available. All these enzymes are highly conserved
homotetrameric proteins (12, 14, 15) with one NAD+ molecule bound into the active site of
each subunit. All residues that interact directly with substrate or cofactor are conserved
among these three enzymes. Such observations and other data (16) suggest that selective
inhibition of parasitic enzymes poses a difficult challenge.
However, it has been reported that Ld-SAHH (from L. donovani) and Tc-SAHH bind NAD+
much less tightly than Hs-SAHH (17), although these parasitic SAHHs bind the reduced
form NADH very tightly and persist in the inactive form containing reduced cofactor (17).
Therefore, the possibility exists to develop highly selective inhibitors for parasitic SAHHs
through designing NAD+ analogues that bind to the cofactor binding site. In this study, we
have investigated NAD+ analogues obtained by modification of the nicotinamide group and
analogues obtained by modification of adenine part (Fig. 1) and compared their inhibitory
effects on Hs- and Tc-SAHHs, to provide information for eventual development of anti-
parasitic drugs.
Materials and Methods
NAD(H) analogues (Fig. 1)
Thionicotinamide adenine dinucleotide (S-NAD), 3-pyridinealdehyde adenine dinucleotide
(H-NAD), 3-acetylpyridine adenine dinucleotide (C-NAD) and its reduced form (C-NADH),
nicotinic acid adenine dinucleotide (O-NAD), nicotinamide hypoxanthine dinucleotide
(NHD) and its reduced form (NHDH), nicotinamide guanine dinucleotide (NGD), and
nicotinamide 1, N6-ethenoadenine dinucleotide (etheno-NAD) were bought from Sigma. The
reduced forms of thionicotinamide adenine dinucleotide (S-NADH) and 3-pyridinealdehyde
adenine dinucleotide (H-NADH) were prepared from the oxidized forms and ethanol with
catalysis by alcohol dehydrogenase (Sigma, A-3263) as follows. A solution (usually 4 ml)
containing 80 U/mL alcohol dehydrogenase, 40 mM ethanol, 4 mM of the oxidized analogue
and 1 mM EDTA in 50 mM phosphate buffer, pH 8.4, was incubated at 25 °C for 30 min
and then filtered on a Centricon column (30k, Millipore) to remove alcohol dehydrogenase.
Reduction of the oxidized forms of H-NAD and S-NAD was analyzed by HPLC by use of
the procedure for enzyme-activity assay described below. H-NAD was completely reduced,
and S-NAD was 90% reduced. Purity was in general determined by HPLC.
Expression and purification of Hs-SAHH and Tc-SAHH
The expression and purification of Hs-SAHH and Tc-SAHH were the same as previously
described (16–18).
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Preparation of apo forms of Hs-SAHH and Tc-SAHH
The apo forms of Hs-SAHH and Tc-SAHHs were prepared by the same method as
previously described (17,18).
Enzyme activity assay
SAHH activity was assayed in the synthetic direction by measuring the rate of formation of
AdoHcy from Ado and Hcy using HPLC as previously described (19,20). The enzyme
activity in the hydrolytic direction was determined by coupling the AdoHcy hydrolysis
reaction to Ado deamination catalyzed by Ado deaminase as previously described (20).
Determination of the degree of occupancy of enzymes reconstituted with NAD(H)
analogues
A solution (1 mL) containing 50 µM apo enzyme (all enzyme concentrations used are
subunit concentrations), 500 µM of an NAD(H) analogue, 0.4 M (NH4)2SO4 and 1 mM
EDTA in 50 mM phosphate buffer, pH 7.4, was incubated for 5 h at 22 °C. The free
analogue that remained was then removed by passage through a PD10 column (GE
healthcare) which had been equilibrated with 50 mM phosphate buffer at 4 °C. The enzyme-
analogue complex was further concentrated by Centricon treatment (30k, Millipore) at 4 °C
and the filtrate was collected to determine the amount of analogue bound. The concentrated
solution of enzyme-analogue complex was mixed with 2 volumes of ethanol, followed by
centrifugation. The precipitated enzyme was re-dissolved and treated with 2 volumes of
ethanol again as above. The supernatants were combined and dried in vacuum. The residue
was then dissolved in water and applied to the HPLC column using the same procedure as
for the enzyme-activity assay. The concentration of each compound was determined by
comparison with a calibration curve obtained from authentic samples.
Determination of the rate constant kon for binding to apo enzyme of NAD+, NADH and NAD
analogues
Typical procedures for determination of the rate constant for binding of NAD+, NGD, NHD,
and etheno-NAD to Hs-SAHH and Tc-SAHH are as follows (17, 18). One µM of Hs-SAHH
apo enzyme was mixed with 5 µM NAD+ or 100 µM NAD+ analogue and the resulting
solution was pre-incubated at 37 °C for 5 min. For binding to the Tc-SAHH apo enzyme of
NAD+ and its analogues, the procedure was the same except that the concentrations of
NAD+ or its analogues were 25 µM and 500 µM, respectively. Samples were taken for
activity assay after selected time periods. The measured activities A were either converted to
the amount of enzyme:NAD+ complex or enzyme:analogue complex or used directly in eq.
1.
(1)
Here, A is the activity measured at time t, Ao is the activity at the apparent time zero
(reflecting reaction during the dead-time of the experiment), Af is the activity at the end of
the experiment, and kapp is a first-order rate constant for association that generally will be a
function of [NAD+] or [NAD+ analogue]. Under the above measurement conditions, Ao is
quite small and kapp is approximately proportional to [NAD+] or [NAD+ analogue]. An
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apparent second-order rate constant kon for the association reaction was therefore calculated
as kon = kapp/[NAD+] or kon = kapp/[NAD+ analogue] for the analogue and kon was used in
the calculation of the equilibrium dissociation constant.
For measurement of kon for NADH, the bound NADH was monitored by fluorescence as
previously described (19).
Determination of the rate constants koff for dissociation of NAD+ and NAD(H) analogues
from their complexes with Hs-SAHH and Tc-SAHH
Determination of koff for the dissociation of NAD+, NGD, NHD and etheno-NAD from
complexes with either Hs-SAHH or Tc-SAHH was carried out as follows. A solution
(usually 4 ml) containing 4 µM SAHH, 80 U/ml alcohol dehydrogenase, 30 mM 2-propanol,
2 mM NADH and 1 mM EDTA in 50 mM phosphate buffer, pH7.4, was incubated at a
chosen temperature. Samples were taken after selected time periods for determination of
enzyme activity and NADH content. NADH concentration did not change during all these
experimental periods. As a control, the stability of SAHH was also determined under the
same conditions as above except in the absence of NADH and alcohol dehydrogenase. The
enzyme activities relative to initial activity were plotted against time and fitted to A/Ao =
exp(−k*t), where A/Ao is the relative activity and k is the enzyme inactivation rate constant.
Enzyme thermal inactivation rate constants were obtained by the same method. The
dissociation rate constants for NAD+ and NAD(H) analogues were obtained by subtracting
the enzyme thermal inactivation rate constants from the value of k. For determination of koff
for NADH analogues, the enzyme:(NADH analogue) complex was mixed with 1 mM of
NAD+ and the enzyme-activity recovery rate indicated the rate of the analogue dissociation.
Dissociation constant (Kd)
Equilibrium dissociation constants of NAD+, NGD, NHD and etheno-NAD were calculated
from the relationship Kd = koff/kon. Dissociation constants of NADH, NADH analogues, S-
NAD, H-NAD, O-NAD and C-NAD were calculated by fitting (Microcal Origin 7.0
software) the enzyme activity as a function of ligand concentration in the presence of NAD+
to the following equation, previously derived (17).
Activity0/Activity = 1 + ([Ligand]/ KdLigand)(KdNAD/(KdNAD + [NAD+]).
“Activity0” refers to the enzyme activity in the absence of ligands other than NAD+ and
KdNAD is the known dissociation constant of NAD+.
Inhibition of Tc-SAHH and Hs-SAHH by NAD(H) Analogues
The inhibition of Hs-SAHH and Tc-SAHH activity by the NAD(H) analogues was
investigated by incubation 20 µM of each analogue with Tc-SAHH and Hs-SAHH in 50 mM
phosphate buffer, pH 7.4, containing 50 µM NAD+ at 37 °C for 6 min (Table 5). 50 µM
NAD+ was included because the concentration of NAD+ inside cells was estimated to be in
this general range (21).
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The results consist of the values shown in Tables 1–3.
Table 1 reports that NAD+ analogues can be reconstituted into the active sites of both Hs-
SAHH and Tc-SAHH with 82–98% of the expected unit occupation of one active site in
each of the four monomeric subunits of the homotetramer. Modifications of the adenine ring
lead to occupancies in the lower range and generate catalytic activities at about 40–70% of
that for NAD+. Modifications of the nicotinamide lead to occupancies in the higher range
and catalytic activities at 0–20% of that for NAD+.
Table 2 reports values of kon, the second-order rate constant for association of a ligand with
Hs-SAHH or Tc-SAHH, koff, the first-order rate constant for dissociation of a ligand from
its complex with the enzyme, and Kd, the equilibrium thermodynamic dissociation constant
of a ligand from its complex with the enzyme. The values of kon range from less than 102 to
over 104 M−1s−1, the values of koff from about 10−5 s−1 to nearly 10−1s−1, and the Kd values
from near-nanomolar to millimolar.
Table 3 identifies five compounds that exhibit some selectivity in trapping the cofactor sites
of Tc-SAHH in preference to those of Hs-SAHH during a 6-min incubation period in the
face of a 2.5-fold excess of NAD+.
Discussion
Occupancy and catalytic activity of NAD+ analogues with Hs-SAHH and Tc-SAHH
The data in Table 1 show that NAD+ analogs complex extensively with Hs-SAHH or Tc-
SAHH, the numerical values of occupancy being 4 equivalents of ligand per equivalent of
homotetramer, thus being equal to the expectation for cofactor-site binding. The fact that
five of the seven analogs produce measurable catalytic activity also is consistent with
occupancy of the cofactor site. Further evidence favoring this view is provided by the fact
that modifications of the adenine ring give higher activities and lower occupancies than
modifications of the nicotinamide ring. This combination is consistent with the long-held
view (22) that the adenine “anchor” is more important for binding than for catalysis. The
fact that H-NAD (with an aldehyde side chain) and O-NAD (with a carboxylate side chain)
are the only NAD+ analogues that do not support measurable catalytic activity with Tc-
SAHH renders them the only compounds in this part of the set worthy further consideration
for anti-parasitic agents.
Off-rates, on-rates and affinities for NAD+ and NADH analogues
Table 2 presents these data for all compounds studied. A useful baseline for comparison is
provided by the data for the oxidized cofactor NAD+ and the reduced cofactor NADH with
Hs-SAHH and Tc-SAHH. As previously noted (17, 18), the affinity of both forms of the
cofactor is in the nanomolar range for Hs-SAHH, the result of an off rate constant in the
range of 10−6 s−1 and an on-rate constant in the range of 103 M−1s−1; in contrast, the affinity
of both forms of the cofactor is in the micromolar range for Tc-SAHH, the result of an off-
rate constant in the range of 10−3 to 10−4 s−1 and an on-rate constant in the range of 103 to
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102 M−1s−1. The contrast in cofactor affinities between Hs-SAHH and Tc-SAHH thus arises
mainly from a much faster off-rate constant for the latter, and it is therein one may seek the
opportunity for selective inhibition of Tc-SAHH over Hs-SAHH.
Among the NAD+ analogues, the most promising seemed to be H-NAD, with an aldehydic
side-chain, and O-NAD, with a carboxylate side-chain, which gave no detectable activity
when reconstituted into the active sites of either Hs-SAHH or Tc-SAHH (Table 1). H-NAD
shows an on-rate constant 10-fold larger and an off-rate constant 12-fold larger than NAD+
with Hs-SAHH so that the affinity for Hs-SAHH of H-NAD is not much different from its
affinity for NAD+. With Tc-SAHH, more or less the same thing is observed. The close
similarity to the kinetics for NAD+ does not bode well for successful inhibition in the
presence of NAD+. O-NAD presents no better picture. Its affinity for both Hs-SAHH and
Tc-SAHH is smaller than their affinity for NAD+ by factors of 35–40 and their on-rate
constants are smaller than those for NAD+.
The NADH analogs show generally poorer affinity than NADH with Hs-SAHH (factors of
3– 600) but affinities with Tc-SAHH that, except for NHDH, are weaker than that for
NADH by smaller factors (3–40) and are greater in all cases except NHDH than the affinity
of Tc-SAHH for NAD+, the probable competitor for inhibitor binding in vivo. We conclude
that NADH analogues may offer the best opportunities for selective inhibition of Tc-SAHH.
Inhibition of Hs-SAHH and Tc-SAHH by NAD+ and NADH analogues
Table 3 shows for each analogue with Hs-SAHH and Tc-SAHH the remaining levels of
catalytic activity after a 6-min exposure of the enzyme to 20 µM analogue in the presence of
50 µM NAD+ to simulate competition by intracellular cofactor. Under these conditions, no
significant inhibition of Hs-SAHH occurred with any analogue. Tc-SAHH was reasonably
strongly inhibited only by the NADH analogues S-NADH and H-NADH, with a bit less than
10% activity remaining. These are the only NADH analogues for which the on-rate
constants for Tc-SAHH exceed (S-NADH) or nearly match (H-NADH) the on-rate constant.
This feature may in part enable the effective competition they display.
Conclusion
We would recommend NADH analogues as a possible starting point for the design of anti-
trypanosomal drugs. Although the set of compounds studied herein does not in any sense
approach a thorough exploration of structures in any part of the cofactor, we hope it serves
to support the further study of cofactor analogs. Clearly the modification of the carboxamide
side chain of the nicotinamide ring was more successful than modification of the adenine
ring, in agreement with previous indications of a more intimate binding relationship at the
latter center.1, 22
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Structures of NAD+ and its analogues
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Table 1










NAD+ 0.98±0.04 100 0.96±0.05 100
Modifications in the carboxamide side-chain of the nicotinamide ring
S-NAD 0.91±0.06 1.4±1.1 0.93±0.06 1.3±0.7
H-NAD 0.94±0.08 0 0.98±0.04 0
O-NAD 0.87±0.09 0 0.83±0.08 0
C-NAD 0.88±0.09 21.4±5.2 0.85±0.08 20.5±3.7
Modifications in the adenine ring
NGD 0.84±0.08 46.5±6.8 0.73±0.09 58.5±7.2
Etheno-NAD 0.89±0.07 69.0±5.3 0.88±0.09 80.6±6.4
NHD2 0.84±0.07 38.6±6.1 0.82±0.08 35.2±4.2
a
Errors calculated from three independent measurements.
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Table 3
















Errors calculated from three independent measurements.
b
After incubation with 20 µM analogue, 50 µM NAD+ to simulate intracellular conditions, at pH 7.4 (phosphate buffer) for a period of 6 min.
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